Amicus Therapeutics, Inc.
FOLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,867 | $4,188 | $3,529 | $3,135 |
| - Cash | $214 | $247 | $149 | $245 |
| + Debt | $444 | $445 | $452 | $440 |
| Enterprise Value | $3,097 | $4,386 | $3,833 | $3,330 |
| Revenue | $528 | $399 | $329 | $306 |
| % Growth | 32.3% | 21.3% | 7.8% | – |
| Gross Profit | $475 | $362 | $291 | $271 |
| % Margin | 90% | 90.7% | 88.3% | 88.7% |
| EBITDA | $29 | -$92 | -$200 | -$203 |
| % Margin | 5.6% | -23.1% | -60.6% | -66.4% |
| Net Income | -$56 | -$152 | -$237 | -$250 |
| % Margin | -10.6% | -38% | -71.9% | -82% |
| EPS Diluted | -0.18 | -0.51 | -0.82 | -0.92 |
| % Growth | 64.7% | 37.8% | 10.9% | – |
| Operating Cash Flow | -$34 | -$69 | -$167 | -$202 |
| Capital Expenditures | -$4 | -$7 | -$4 | -$4 |
| Free Cash Flow | -$37 | -$77 | -$170 | -$206 |